NeuroPace, Inc. (NASDAQ:NPCE) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 18.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 488,618 shares of the company's stock after acquiring an additional 75,512 shares during the period. Vanguard Group Inc. owned approximately 1.70% of NeuroPace worth $6,450,000 at the end of the most recent reporting period.

NeuroPace Stock Down 3.2 %

NeuroPace stock traded down $0.22 during trading hours on Friday, hitting $6.87. The stock had a trading volume of 41,293 shares, compared to its average volume of 109,280. The company has a quick ratio of 5.56, a current ratio of 6.43 and a debt-to-equity ratio of 4.05. The stock has a market capitalization of $197.64 million, a P/E ratio of -5.77 and a beta of 1.80. NeuroPace, Inc. has a 12-month low of $4.21 and a 12-month high of $18.15. The stock's 50-day moving average price is $7.16 and its 200-day moving average price is $10.83.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. The business had revenue of $19.26 million during the quarter, compared to analysts' expectations of $18.30 million. NeuroPace had a negative net margin of 45.61% and a negative return on equity of 173.62%. The business's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.36) earnings per share. Equities research analysts anticipate that NeuroPace, Inc. will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

NPCE has been the topic of several research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $18.00 price objective on shares of NeuroPace in a research note on Wednesday. Morgan Stanley dropped their price objective on shares of NeuroPace from $9.50 to $8.00 and set an "equal weight" rating on the stock in a research note on Monday, July 15th. Finally, Wells Fargo & Company dropped their price objective on shares of NeuroPace from $20.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $14.00.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.